GSK To Downplay Europe Because of Poor Innovation Support, Focuses On Japan, U.S. Instead
This article was originally published in PharmAsia News
Executive Summary
GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products.